Research
Brepocitinib yields improvements in cutaneous sarcoidosis
The Brief
- A study in JAMA Dermatology reports that brepocitinib is associated with dose-dependent, clinically meaningful improvements in cutaneous sarcoidosis.
- The study was published online to coincide with the annual meeting of the American College of Rheumatology.
Why it matters
The findings offer a trial-based signal that an investigational drug may improve skin manifestations of sarcoidosis, which matters to clinicians and researchers working on inflammatory skin and systemic disease.
Who’s affected
- dermatologists and rheumatologists
- patients with cutaneous sarcoidosis
- #sarcoidosis
- #brepocitinib
- #dermatology
- #clinical trial
- #rheumatology
For patients with cutaneous sarcoidosis (CS), brepocitinib is associated with dose-dependent and clinically meaningful improvements, according to a study published online in JAMA Dermatology to coincide with the annual meeting of the American College of Rheumatology, held from…